Objective: The objective was to determine the degree of toxicity and antitu
mor activity following bronchoscopic injection of an adenoviral-mediated p5
3 gene (Adp53) into tumors causing airway obstruction.
Dosing: This was a subset analysis of a phase I dose escalation trial.
Setting: Patients were treated in the outpatient clinics at the University
of Texas (MD Anderson Cancer Center, Houston, TX) and at Medical City Dalla
s Hospital (US Oncology, Dallas, TX).
Patients: Twelve patients (median age, 60 years) with advanced endobronchia
l non-small cell lung cancer (NSCLC) (squamous cell carcinoma, six patients
; adenocarcinoma, six patients) were entered into trial. The median tumor a
rea was 5 x 3.2 cm. All patient tumors contained a p53 gene mutation.
Interventions: Adp53 (dose range, 1 x 10(6) to 1 x 10(11) plaque-forming un
its) was administered by bronchoscopic intratumoral injection once every 28
days.
Measurements and results: Toxicity attributed to the Adp53 vector was minim
al. Six of the 12 patients had significant improvement in airway obstructio
n, and 3 patients met the criteria for partial response.
Conclusions: Direct bronchoscopic injection of Adp53 into endobronchial NSC
LC is safe, with acceptable levels of toxicity. The initial clinical result
s demonstrating relief of airway obstruction warrant further clinical inves
tigation.